Tag: prophylaxis
-
Immune Complications Drive Higher Infection Risk in Advanced Myeloma Therapies
Overview: A New Frontier in Multiple Myeloma Treatment Chimeric Antigen Receptor (CAR T-cell) therapy and bispecific antibody (BsAb) therapy have transformed the management of advanced multiple myeloma (MM). These immunotherapies mobilize the patient’s own immune system to target and destroy malignant plasma cells, offering durable responses for many who have exhausted conventional therapies. Yet, with…
-
Immune Complications Elevate Infection Risk in MM Therapies
Overview: Why Immune Complications Matter in Advanced Multiple Myeloma Therapies Chimeric Antigen Receptor (CAR-T) cell therapy and bispecific antibodies (BsAbs) have transformed the treatment landscape for multiple myeloma (MM), offering deep and durable responses for patients with relapsed or refractory disease. Yet, these immune-based therapies also bring new challenges. Immune complications, including impaired humoral and…